MITO23: Phase III Trial of Trabectedin vs Investigator’s Choice of Chemotherapy for Recurrent Ovarian Cancer With BRCA Mutation or BRCAness Phenotype

June 3-7, 2022; Chicago, Illinois
In MITO23, trabectedin failed to improve survival compared with investigator’s choice of single-agent chemotherapy in patients with BRCA-mutant or BRCAness phenotype recurrent ovarian cancer.
Format: Microsoft PowerPoint (.ppt)
File Size: 136 KB
Released: June 17, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline
Merck Sharp & Dohme Corp.
Seattle Genetics

Related Content

Interactive online tool with expert management recommendations for selecting therapy for women with ovarian cancer, from Clinical Care Options (CCO)

Robert L. Coleman, MD, FACOG, FACS Linda R. Duska, MD, MPH Thomas J. Herzog, MD person default Kathleen Moore, MD person default David O'Malley, MD Released: August 5, 2022

Gain important nursing insights on the management of patients with gynecologic cancers in this program from Clinical Care Options (CCO)

person default Courtney Arn, CNP Released: August 2, 2022

Downloadable HCP resource with recommendations for monitoring/managing ocular adverse events with antibody-drug conjugates used to treat gynecologic cancers, from Clinical Care Options (CCO)

Released: July 27, 2022

Commentary on evolving treatment paradigms in gynecologic cancers, from Clinical Care Options (CCO)

David Scott Miller, MD, FACOG, FACS
Program Director
Nicoletta Colombo, MD Shannon N. Westin, MD, MPH
Released: July 14, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings